Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety bucket trial with NVDX3
2024-511661-11-01Phase 2Authorised
- Sponsor
- Novadip Biosciences
- Start
- Jul 2024
- Modality
- Cell Therapies, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NVD-X3 in distal forearm fracture and degenerative spondylolisthesis (DS), sponsored by Novadip Biosciences. Primary endpoint: Long-term safety outcomes. Planned start Jul 2024; status: authorised.
02
Drugs
NVD-X3
03
Conditions
distal forearm fracturedegenerative spondylolisthesis (DS)
Beyond the preview
Go deeper on 2024-511661-11-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511661-11-01.